Article
Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer.
Cancer discovery - 6 Feb 2026
Gumpert Nofar, Sagie Shira, Arnedo-Pac Claudia, Babu Tomer, Weller Chen, Gonzalez-Perez Abel, Wang Yuan, Michel Todó Lucas, Levy Ronen, Chen Xi, Greenberg Polina, Dayan-Rubinov Maria, Yakubovich Elizabeta, Wasserman-Bartov Talya, Zerbib Mirie, Gong Jianhui, Rebernick Ryan J, Oliveira Tercero Anna, Agundez Muriel Laura, Benedek Gil, Kedmi Merav, Oren Roni, Ben-Dor Shifra, Levin Yishai, Troyanskaya Olga G, Munzur Aslı D, Wyatt Alexander W, Cieslik Marcin P, Quigley David A, Van Allen Eliezer M, Anandasabapathy Niroshana, Mateo Joaquin, Yang Xinbo, Martínez-Jiménez Francisco, Lopez-Bigas Nuria, Samuels Yardena
Abstract excerpt
New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.